Nexalin Technology, Inc.
A filing-based review of operating performance, liquidity, equity financing, material corporate developments and documented capital-market events.
1. Business and financial performance
Exchange compliance issues are distinct from the merits of its medical technology. Nevertheless, a limited equity cushion can complicate funding and may require capital actions that dilute existing shareholders.
Nexalin’s August 2026 8-K disclosed a Nasdaq stockholders’ equity deficiency: its June 30, 2026 reported stockholders’ equity was $1,519,423, below the $2.5 million continued-listing threshold. The company also described an earlier minimum-bid-price deficiency.
2. Liquidity and going concern
A separate, filing-supported assessment of liquidity and going-concern status is not established in this edition.
3. Equity financing and dilution
The compliance notices are documented facts; they are not proof of insolvency or that delisting is inevitable. Financing transactions and subsequent Nasdaq decisions could materially change the situation.
4. Exchange listing and trading events
No exchange-listing or trading event has been established from the source material included in this edition.
5. Strategic developments and corporate actions
Exchange compliance issues are distinct from the merits of its medical technology. Nevertheless, a limited equity cushion can complicate funding and may require capital actions that dilute existing shareholders.
Primary document: Review underlying regulatory source ↗
6. Evidence ledger
7. Research conclusion
The evidence included in this edition is insufficient for a directional investment conclusion.
Documented filing analysis: Equity financing dependence and exchange compliance
Nexalin’s June 2026 Form 10-Q describes historical reliance on equity financings, including at-the-market sales, and states that additional capital may be needed for planned operations. This identifies external financing as a material element of the company’s funding model rather than an incidental source of cash.
The filing describes a July 24, 2026 Nasdaq Staff Delisting Determination and the company’s request for a hearing. The ability to access registered ATM capital depends in part on listing and Form S-3 eligibility; therefore, listing outcomes may influence the company’s future financing flexibility.
Primary document: Open underlying filing or issuer document ↗
Independent research and non-compensation disclosure
Unsolicited, non-sponsored proprietary research. AnalystPitch.com independently selected Nexalin Technology, Inc. as the subject of this report and initiated its preparation and publication on its own initiative. Nexalin Technology, Inc. did not request, commission, sponsor, direct, or authorize this publication and had no involvement in the research process, editorial decisions, or approval of the report.
Compensation received or promised for this publication: US$0.00. AnalystPitch.com states that it has received no cash, securities, warrants, options, expense reimbursement, or other direct or indirect consideration from Nexalin Technology, Inc. or anyone acting on its behalf in exchange for preparing, publishing, or distributing this report, and that no such consideration has been promised. This report is not paid securities promotion or issuer-sponsored research.
Section 17(b) transparency. Section 17(b) of the Securities Act of 1933 addresses certain securities publicity published for consideration received directly or indirectly from an issuer, underwriter, or dealer. The compensation statement above describes the circumstances of this report; it is not a claim that the SEC has reviewed, approved, or certified the report or this disclosure.
Other potential conflicts. The absence of payment for this publication does not by itself establish the absence of other financial interests or relationships. Any material securities holdings, financing arrangements, advisory engagements, or other relevant conflicts involving the publisher or its responsible contributors should be separately disclosed where applicable.
This publication is informational research, not personalized investment advice, an offer to sell securities, or a solicitation to purchase securities.
9. Primary documents
Primary referenced regulatory filing or source ↗
SEC EDGAR — search subsequent company filings ↗
Information cutoff: 13 October 2026. Not all financial line items have been independently recalculated. This report does not purport to reproduce a full audited financial model. Information can become outdated after the cutoff.